126 related articles for article (PubMed ID: 29477137)
1. Taiwanofungus camphoratus Combined With Amphotericin B for Metastatic Cancer Patients Unresponsive to or Unwilling to Undergo Chemotherapy: A Pilot Study.
Tai CJ; Shi YC; Tai CJ; Kuo LJ; Chen RJ; Chang YJ; Tzao C; Wu CH; Chang CC; Chiou HY; Su CH
Altern Ther Health Med; 2020 Mar; 26(2):18-22. PubMed ID: 29477137
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment with an ethanolic extract of Taiwanofungus camphoratus (Antrodia camphorata) enhances the cytotoxic effects of amphotericin B.
Chen LY; Sheu MT; Liu DZ; Liao CK; Ho HO; Kao WY; Ho YS; Lee WS; Su CH
J Agric Food Chem; 2011 Oct; 59(20):11255-63. PubMed ID: 21899275
[TBL] [Abstract][Full Text] [Related]
3. Taiwanofungus camphoratus (Syn Antrodia camphorata) extract and amphotericin B exert adjuvant effects via mitochondrial apoptotic pathway.
Chen LY; Sheu MT; Liao CK; Tsai FC; Kao WY; Su CH
Integr Cancer Ther; 2013 Mar; 12(2):153-64. PubMed ID: 22791310
[TBL] [Abstract][Full Text] [Related]
4. The Ethanolic Extract of Taiwanofungus camphoratus (Antrodia camphorata) Induces Cell Cycle Arrest and Enhances Cytotoxicity of Cisplatin and Doxorubicin on Human Hepatocellular Carcinoma Cells.
Lin LT; Tai CJ; Su CH; Chang FM; Choong CY; Wang CK; Tai CJ
Biomed Res Int; 2015; 2015():415269. PubMed ID: 26557666
[TBL] [Abstract][Full Text] [Related]
5. Successful management of chronic disseminated candidiasis in hematologic patients treated with high-dose liposomal amphotericin B: a retrospective study of the SEIFEM registry.
Della Pepa R; Picardi M; Sorà F; Stamouli M; Busca A; Candoni A; Delia M; Fanci R; Perriello V; Zancanella M; Nosari A; Salutari P; Marchesi F; Pane F; Pagano L;
Support Care Cancer; 2016 Sep; 24(9):3839-45. PubMed ID: 27075673
[TBL] [Abstract][Full Text] [Related]
6. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
[TBL] [Abstract][Full Text] [Related]
7. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
Brogden RN; Goa KL; Coukell AJ
Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
[TBL] [Abstract][Full Text] [Related]
8. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.
Cannon JP; Garey KW; Danziger LH
Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200
[TBL] [Abstract][Full Text] [Related]
9. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
[TBL] [Abstract][Full Text] [Related]
10. Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.
Rothenbühler C; Held U; Manz MG; Schanz U; Gerber B
Hematol Oncol; 2018 Apr; 36(2):471-480. PubMed ID: 29431860
[TBL] [Abstract][Full Text] [Related]
11. Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.
Annino L; Chierichini A; Anaclerico B; Finolezzi E; Norata M; Cortese S; Cassetta MI; Fallani S; Novelli A; Girmenia C
Antimicrob Agents Chemother; 2013 Jun; 57(6):2596-602. PubMed ID: 23529741
[TBL] [Abstract][Full Text] [Related]
12. Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study.
Azoulay E; Timsit JF; Lautrette A; Legriel S; Max A; Ruckly S; Misset B; Cohen Y; Wolff M
PLoS One; 2017; 12(5):e0177093. PubMed ID: 28531175
[TBL] [Abstract][Full Text] [Related]
13. A preliminary randomised controlled study of short-term Antrodia cinnamomea treatment combined with chemotherapy for patients with advanced cancer.
Tsai MY; Hung YC; Chen YH; Chen YH; Huang YC; Kao CW; Su YL; Chiu HH; Rau KM
BMC Complement Altern Med; 2016 Aug; 16(1):322. PubMed ID: 27565426
[TBL] [Abstract][Full Text] [Related]
14. Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: a prospective, randomized, open-label, placebo-controlled pilot study.
Arrieta AC; Shea K; Dhar V; Cleary JP; Kukreja S; Morris M; Vargas-Shiraishi OM; Ashouri N; Singh J
Clin Ther; 2010 Feb; 32(2):265-71. PubMed ID: 20206784
[TBL] [Abstract][Full Text] [Related]
15. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis.
Lewis RE; Albert ND; Liao G; Hou J; Prince RA; Kontoyiannis DP
Antimicrob Agents Chemother; 2010 Mar; 54(3):1298-304. PubMed ID: 20038620
[TBL] [Abstract][Full Text] [Related]
17. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.
Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S
J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283
[TBL] [Abstract][Full Text] [Related]
18. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
[TBL] [Abstract][Full Text] [Related]
19. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem cell transplant patients.
Gubbins PO; Amsden JR; McConnell SA; Anaissie EJ
Antimicrob Agents Chemother; 2009 Sep; 53(9):3664-74. PubMed ID: 19546359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
